# Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

Study · id `cardio:ct-nct01212913` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01212913](<https://clinicaltrials.gov/study/NCT01212913>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01212913

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT01212913. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT01212913, source copy `cardio:ctgov-nct01212913-2013-07-08`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01212913, source copy `cardio:ctgov-nct01212913-2013-07-08`, retrieved 2026-10-26)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01212913, source copy `cardio:ctgov-nct01212913-2013-07-08`, retrieved 2026-10-26)
- Completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01212913, source copy `cardio:ctgov-nct01212913-2013-07-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01212913, source copy `cardio:ctgov-nct01212913-2013-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01212913-2013-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
- Acronym: B to B
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): INSULIN GLARGINE
- Intervention (Drug): INSULIN GLULISINE
- Intervention (Drug): Insulin aspart
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial (`cardio:pubmed-25952532`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3342afb293ef575cc10f1afb0a9f186db032a310342a7cbc2daf73577b6b6b73
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
